At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01.

IQVIA has partnered with SCRI Development Innovations, the contract research organisation side of the Sarah Cannon Research ...

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...

AviadoBio has opened the multi-centre Phase I/II ASPIRE-FTD trial in the UK, aimed at assessing the gene therapy candidate ...

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with daraxonrasib (RMC-6236) for NSCLC.

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

Nuance Pharma’s Ohtuvayre has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in ...